99 related articles for article (PubMed ID: 8436341)
1. p53 protein expression in non-neoplastic lesions and benign and malignant neoplasms of soft tissue.
Dei Tos AP; Doglioni C; Laurino L; Barbareschi M; Fletcher CD
Histopathology; 1993 Jan; 22(1):45-50. PubMed ID: 8436341
[TBL] [Abstract][Full Text] [Related]
2. p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas.
Wadayama B; Toguchida J; Yamaguchi T; Sasaki MS; Yamamuro T
Br J Cancer; 1993 Dec; 68(6):1134-9. PubMed ID: 8260365
[TBL] [Abstract][Full Text] [Related]
3. Abnormalities of p53 and p110RB tumor suppressor gene expression in human soft tissue tumors: correlations with cell proliferation and tumor grade.
Wang J; Coltrera MD; Gown AM
Mod Pathol; 1995 Oct; 8(8):837-42. PubMed ID: 8552572
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
[TBL] [Abstract][Full Text] [Related]
5. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
6. Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas.
Mousses S; McAuley L; Bell RS; Kandel R; Andrulis IL
Mod Pathol; 1996 Jan; 9(1):1-6. PubMed ID: 8821948
[TBL] [Abstract][Full Text] [Related]
7. Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone.
Ueda Y; Dockhorn-Dworniczak B; Blasius S; Mellin W; Wuisman P; Böcker W; Roessner A
J Cancer Res Clin Oncol; 1993; 119(3):172-8. PubMed ID: 8418091
[TBL] [Abstract][Full Text] [Related]
8. Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: a retrospective immunohistological study including 216 soft tissue sarcomas.
Jensen V; Sørensen FB; Bentzen SM; Ladekarl M; Nielsen OS; Keller J; Jensen OM
Histopathology; 1998 Jun; 32(6):536-46. PubMed ID: 9675593
[TBL] [Abstract][Full Text] [Related]
9. Expression of P53, MDM2 and Ki-67 antigens in soft tissue sarcomas.
Szadowska A; Olborski B; Harezga-Bal B; Debiec-Rychter M
Pol J Pathol; 1999; 50(1):9-16. PubMed ID: 10412269
[TBL] [Abstract][Full Text] [Related]
10. p53 protein expression in benign and malignant skin tumours.
Ro YS; Cooper PN; Lee JA; Quinn AG; Harrison D; Lane D; Horne CH; Rees JL; Angus B
Br J Dermatol; 1993 Mar; 128(3):237-41. PubMed ID: 8471506
[TBL] [Abstract][Full Text] [Related]
11. Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue.
Porter PL; Gown AM; Kramp SG; Coltrera MD
Am J Pathol; 1992 Jan; 140(1):145-53. PubMed ID: 1731521
[TBL] [Abstract][Full Text] [Related]
12. Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma: identification of seven new mutations for soft tissue sarcomas.
Taubert H; Würl P; Meye A; Berger D; Thamm B; Neumann K; Hinze R; Schmidt H; Rath FW
Cancer; 1995 Oct; 76(7):1187-96. PubMed ID: 8630896
[TBL] [Abstract][Full Text] [Related]
13. Immunophenotype, ras oncogenes and p53 onco-suppressor gene in benzo(a)pyrene induced malignant soft tissue tumours in Wistar rats.
Stefanou DG; Nonni AV; Kalpouzos G; Evangelou A; Agnantis NJ
In Vivo; 1998; 12(5):511-21. PubMed ID: 9827359
[TBL] [Abstract][Full Text] [Related]
14. Significance of AgNOR score in benign and malignant soft tissue tumours.
Khan N; Sood P; Vasenwala SM; Afroz N; Verma AK
Indian J Pathol Microbiol; 2006 Jan; 49(1):17-20. PubMed ID: 16625965
[TBL] [Abstract][Full Text] [Related]
15. Nuclear immunoreaction of p53 protein in soft tissue sarcomas. A possible prognostic factor.
Kawai A; Noguchi M; Beppu Y; Yokoyama R; Mukai K; Hirohashi S; Inoue H; Fukuma H
Cancer; 1994 May; 73(10):2499-505. PubMed ID: 8174045
[TBL] [Abstract][Full Text] [Related]
16. Histiocyte-like cells expressing factor XIIIa do not belong to the neoplastic cell population in malignant fibrous histiocytoma.
Szollosi Z; Nemeth T; Egervari K; Nemes Z
Pathol Res Pract; 2005; 201(5):369-77. PubMed ID: 16047946
[TBL] [Abstract][Full Text] [Related]
17. p53 immunoreactivity in human malignant melanoma and dysplastic naevi.
McGregor JM; Yu CC; Dublin EA; Barnes DM; Levison DA; MacDonald DM
Br J Dermatol; 1993 Jun; 128(6):606-11. PubMed ID: 8338744
[TBL] [Abstract][Full Text] [Related]
18. Localization of p53 protein and human papillomavirus in anogenital squamous lesions: immunohistochemical and in situ hybridization studies in benign, dysplastic, and malignant epithelia.
Walts AE; Koeffler HP; Said JW
Hum Pathol; 1993 Nov; 24(11):1238-42. PubMed ID: 8244324
[TBL] [Abstract][Full Text] [Related]
19. P53 overexpression in human soft tissue sarcomas: relation to biological aggressiveness.
Toffoli G; Doglioni C; Cernigoi C; Frustaci S; Perin T; Canal B; Boiocchi M
Ann Oncol; 1994 Feb; 5(2):167-72. PubMed ID: 8186161
[TBL] [Abstract][Full Text] [Related]
20. Cell-type- and tumour-type-related patterns of bcl-2 reactivity in mesenchymal cells and soft tissue tumours.
Miettinen M; Sarlomo-Rikala M; Kovatich AJ
Virchows Arch; 1998 Sep; 433(3):255-60. PubMed ID: 9769129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
